Roche CEO to step down in 2008, first-half sales up 15%

Share this article:

Roche said yesterday its CEO Franz Humer will leave his post in March 2008 as the company separates its chief executive and chairman's jobs.

Humer, 61, will remain the company's chairman of the board. He will be replaced as CEO by Severin Schwan, leader of Roche's diagnostics division since last January. At age 40, Schwan will be the youngest CEO ever for the Swiss drugmaker. Schwan has worked at Roche since 1993, when he joined the company as a finance officer in Basel.

Meanwhile, Humer will take on responsibilities as chairman of Diageo, the world's biggest liquor company, next July. Humer, 61, became a non-executive board member at Diageo in 2005.

Roche also reported yesterday that its first-half sales rose 15% to $19 billion with sales of prescription drugs up 17% to $15.2 billion.

The drug maker benefited from sales of its flu treatment Tamiflu, which saw sales rise 39% in the first half to $1.1 billion.

Roche's top-selling Rx drug, MabThera for non-Hodgkin's lymphoma, saw a first-half sales increase of 16% to $2.25 billion. Breast cancer drug Herceptin's first-half sales rose 30% in to nearly $2 billion. Tumor treatment Avastin sales were up 40% in the first-half to $1.6 billion.  

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.